Efficacy and safety of selegiline across different psychiatric disorders

Autor: Flavia Rossano, Claudio Caiazza, Andrea Sobrino, Niccolò Solini, Alessandro Vellucci, Nicolas Zotti, Michele Fornaro, Ken Gillman, Carlo Ignazio Cattaneo, Vincent Van den Eynde, Tom K. Birkenhager, Henricus G. Ruhé, Stephen Stahl, Felice Iasevoli, Andrea de Bartolomeis

Publikováno v: European Neuropsychopharmacology, 72, 60-78. Elsevier
European neuropsychopharmacology
Rossano, F, Caiazza, C, Sobrino, A, Solini, N, Vellucci, A, Zotti, N, Fornaro, M, Gillman, K, Cattaneo, C I, van den Eynde, V, Birkenhager, T K, Ruhé, H G, Stahl, S, Iasevoli, F & de Bartolomeis, A 2023, ' Efficacy and safety of selegiline across different psychiatric disorders : A systematic review and meta-analysis of oral and transdermal formulations ', European Neuropsychopharmacology, vol. 72, pp. 60-78 . https://doi.org/10.1016/j.euroneuro.2023.03.012
European Neuropsychopharmacology, 72, 60-78
European Neuropsychopharmacology, 72, pp. 60-78

Selegiline is an irreversible, selective type-B monoamine oxidase inhibitor (MAOI) approved for Parkison's disease-oral and major depressive disorder-transdermal formulation) result-ing in non-selective MAOI activity at oral doses >20 mg/day. The pre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::469fbb9eec6ee8b1011410740b411049
https://doi.org/10.1016/j.euroneuro.2023.03.012